SciComPro partners with Community Research for medical device trials

By Alexandria Pesic

- Last updated on GMT

SciComPro, life sciences consultancy firm based in Ohio, US, has partnered with clinical trials specialist, Community Research, to conduct clinical trials for a number of new medical device products.

Kurt Weingand, president of SciComPro, will serve as principal investigator in the trials, which will take place at Community Research’s Red Bank Expressway site in Cincinnati, US.

Speaking to, Weingand explained more about his upcoming role, and why SciComPro decided to partner with Community Research.

“I will be testing new prototypes of topical modality devices for treatment of muscle and joint pain and stiffness,” ​he said.

“Community Research has a large clinical research facility that allows for studies of topical modality products while subject are awake and active or while lying in bed. Sleep research is a core expertise at Community Research.”

Trial procedures

Weigand went on to explain little more about what the trials will entail and what processes will be involved.

“In general, healthy subjects will wear a variety of topical modality devices on various body regions for several hours. Subjects will then be evaluated every 20 to 30 minutes for device performance and safety,” ​he said.

According to Weingand, community Research will lead subject recruitment, and “the execution of several technical methods for evaluating device product performance and safety”

Commenting on the announcement, David Mayleben, president of Community Research, said: “We are delighted to have Dr. Weingand working with our Community Research team.”

Market demand

When asked about the state of the current market for topical modality devices, Weingand said the sector has experience rapid growth.

“The category of topical modality devices for treating muscle and joint pain and stiffness has grown considerably during the past ten years,” ​he said.

“Consumers often use topical modalities as a supplement to oral analgesic medications for treating pain and stiffness of muscles and joints.”

Weingand has a 20 year history working in research and development for Procter & Gamble’s Global Health & Well-Being business unit. Prior to working at P&G, he was a faculty member at Wake Forest University’s School of Medicine, in North Carolina, US.

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers